4-(甲基氨基)丁基氨基甲酸叔丁酯 | 874831-66-0

• 物质功能分类: 有机原料 - 氨基化合物 - 含氧基氨基化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-(甲基氨基)丁基氨基甲酸叔丁酯
• 中文别名: 1-(BOC-氨基)-4-(甲氨基)丁烷
• 英文名称: tert-butyl (4-(methylamino)butyl)carbamate
• 英文别名: tert-butyl N-[4-(methylamino)butyl]carbamate
• CAS: 874831-66-0
• 化学式: C₁₀H₂₂N₂O₂
• 分子量: 202.297
• InChiKey: TTYVTUUWVLXDKW-UHFFFAOYSA-N

物化性质

• 沸点：
  298.2±23.0 °C(Predicted)
• 密度：
  0.941±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924199090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: tert-Butyl 4-(methylamino)butylcarbamate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl 4-(methylamino)butylcarbamate
CAS number: 874831-66-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H22N2O2
Molecular weight: 202.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(甲基氨基)丁基氨基甲酸叔丁酯 在 磺酰胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.5h， 以64%的产率得到tert-butyl 4-(methyl(sulfamoyl)amino)butylcarbamate
  参考文献：
  名称：

  [EN] MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS
  [FR] DÉRIVÉS D'INDOLE MACROCYCLIQUES UTILES COMME INHIBITEURS DU VIRUS DE L'HÉPATITE C

  摘要：

  HCV复制抑制剂的化学式（I），包括立体化学异构体形式，以及其盐、水合物、溶剂合物，其中R1、R2、R4、R5、R6和R7的含义如权利要求中所定义。本发明还涉及制备所述化合物的方法、含有它们的药物组合物以及它们在HCV治疗中的应用。

  公开号：

  WO2010003658A1
• 作为产物：
  描述：

  4-(N-叔丁氧羰基氨基)-1-丁醇 在 四溴化碳 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 19.0h， 生成 4-(甲基氨基)丁基氨基甲酸叔丁酯
  参考文献：
  名称：

  [EN] HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE
  [FR] COMPOSÉS HÉTÉROBIFONCTIONNELS ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES

  摘要：

  The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC which is linked to a moiety that binds to a target protein selected from BTK, androgen receptor or IDH1. Pharmaceutical compositions and their use in treating disease, such as cancer, are also disclosed.

  公开号：

  WO2023059583A1

文献信息

• NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK)
  申请人：Shapiro Paul S.

  公开号：US20140179743A1

  公开（公告）日：2014-06-26

  A compound, having the formula A-1: Wherein R 1 and R 2 are defined herein. Methods of using the compound and compositions containing the compound are provided.

  一个具有化学式A-1的化合物，其中R1和R2在此处被定义。提供了使用该化合物的方法和含有该化合物的组合物。
• [EN] DEGRADERS OF WEE1 KINASE<br/>[FR] AGENTS DE DÉGRADATION DE LA KINASE WEE1
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2020069105A1

  公开（公告）日：2020-04-02

  Disclosed are bifunctional compounds (degraders) that target Wee1 tyrosine kinase for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.

  披露了一种靶向Wee1酪氨酸激酶进行降解的双功能化合物（降解剂）。还披露了含有这些降解剂的药物组合物以及使用这些化合物治疗疾病的方法。
• [EN] MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS<br/>[FR] DÉRIVÉS D'INDOLE MACROCYCLIQUES UTILES COMME INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：TIBOTEC PHARM LTD

  公开号：WO2010003658A1

  公开（公告）日：2010-01-14

  Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1, R2, R4, R5, R6 and R7 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

  HCV复制抑制剂的化学式（I），包括立体化学异构体形式，以及其盐、水合物、溶剂合物，其中R1、R2、R4、R5、R6和R7的含义如权利要求中所定义。本发明还涉及制备所述化合物的方法、含有它们的药物组合物以及它们在HCV治疗中的应用。
• Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor
  作者：Liyang Shi、Zhenpeng Zhong、Xitao Li、Yiqing Zhou、Zhengying Pan

  DOI：10.1021/acs.jmedchem.8b01823

  日期：2019.1.24

  pharmacokinetic properties. Thus, it may serve as a highly valuable tool molecule to study the overlapping roles of JAK family kinases in complex biological settings. Our study also suggested that for covalent kinase inhibitors, especially those targeting kinases with low Km ATP values, the reversible interactions between molecules and proteins should be carefully optimized to improve the overall potency.

  JAK家族激酶是免疫细胞信号传导的重要介体，Janus激酶3（JAK3）长期以来一直被视为自身免疫性疾病的潜在靶标。开发高选择性JAK3抑制剂的努力已经很多年了。但是，由于JAK3对5'-三磷酸腺苷（ATP）的强烈结合偏好，许多抑制剂在酶和细胞效能之间显示出较大的差距，这阻碍了剖析JAK3在细胞环境中的作用。使用靶向共价抑制剂方法，我们发现了化合物32，该化合物克服了酶促测定中的ATP竞争（1 mM），并证明了对小鼠CTLL-2和人外周血单核细胞中JAK3依赖性信号传导的抑制活性显着提高。化合物32在JAK家族中还显示出高选择性和良好的药代动力学特性。因此，它可能是一种非常有价值的工具分子，用于研究JAK家族激酶在复杂生物学环境中的重叠作用。我们的研究还表明，对于共价激酶抑制剂，尤其是那些针对具有低K m ATP值的激酶的抑制剂，应仔细优化分子与蛋白质之间的可逆相互作用，以提高整体效能。
• HETEROARYL COMPOUNDS AND USES THEREOF
  申请人：Singh Juswinder

  公开号：US20100016296A1

  公开（公告）日：2010-01-21

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物，其药学上可接受的组成物和使用它们的方法。